🟡Relating to the establishment of a program to fund FDA drug development trials with ibogaine and the administration of that treatment.
(Note: The conference and later prints shift to a consortium model with revenue allocation provisions while earlier prints describe a grant to a single applicant and include a stand-alone subchapter on medical supervision.)

🟡 SB 2308: State-backed ibogaine drug trial consortium

What it says it does:
Creates a program at the Health and Human Services Commission to fund FDA drug trials for ibogaine as a treatment for opioid addiction and related conditions.

What it actually changes:
Instead of a broad grant pool, it funnels state and private matching funds into a single consortium made up of a drug developer, a Texas university, and a hospital with intensive cardiac care. The state also takes a share of any commercialization revenue, with a portion earmarked for veterans’ programs.

Who is pushing for it:
Support noted in the files from the Meadows Mental Health Policy Institute, Texas Medical Association, National Association of Social Workers Texas Chapter, Veterans Exploring Treatment Solutions, Breakthrough Therapies Initiative, American Ibogaine Initiative, and several veteran advocates.

Who benefits:
Large universities, major hospital systems with ICU capacity, biotech developers that can raise matching funds, and veteran-focused programs if revenue eventually flows.

Who gets left out or exposed:
Smaller clinics, rural providers, and less capitalized researchers cannot qualify. Patients and veterans may face delays if commercialization revenue is slow to arrive.

Why this matters long term:
It sets a precedent for Texas to act like an investor in drug development. That means future projects could bypass standard procurement, concentrate power in a few institutions, and tie public services to uncertain pharmaceutical revenues.

What to watch next:
Which consortium HHSC selects, how matching funds are raised, and whether reporting and audit controls are strong enough to ensure transparency.

Bottom line:
This bill aims to put Texas at the front of addiction research, but it centralizes power in a narrow group and relies on speculative revenues that may or may not materialize.